Taiwan Bio Therapeutics Co., Ltd
Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei City, Taiwan.
Market Cap & Net Worth: Taiwan Bio Therapeutics Co., Ltd (6892)
Taiwan Bio Therapeutics Co., Ltd (TWO:6892) has a market capitalization of $70.95 Million (NT$2.35 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #45313 globally and #2011 in its home market, demonstrating a -3.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Taiwan Bio Therapeutics Co., Ltd's stock price NT$27.65 by its total outstanding shares 84898751 (84.90 Million).
Taiwan Bio Therapeutics Co., Ltd Market Cap History: 2026 to 2026
Taiwan Bio Therapeutics Co., Ltd's market capitalization history from 2026 to 2026. Data shows growth from $70.95 Million to $70.95 Million (0.00% CAGR).
Taiwan Bio Therapeutics Co., Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Taiwan Bio Therapeutics Co., Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6892 by Market Capitalization
Companies near Taiwan Bio Therapeutics Co., Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Taiwan Bio Therapeutics Co., Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Taiwan Bio Therapeutics Co., Ltd Historical Marketcap From 2026 to 2026
Between 2026 and today, Taiwan Bio Therapeutics Co., Ltd's market cap moved from $70.95 Million to $ 70.95 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$70.95 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Taiwan Bio Therapeutics Co., Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.95 Million USD |
| MoneyControl | $70.95 Million USD |
| MarketWatch | $70.95 Million USD |
| marketcap.company | $70.95 Million USD |
| Reuters | $70.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.